See more : BlueVenture Group Public Company Limited (BVG.BK) Income Statement Analysis – Financial Results
Complete financial analysis of MicroTech Medical (Hangzhou) Co., Ltd. (2235.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MicroTech Medical (Hangzhou) Co., Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- IGas Energy plc (IGESF) Income Statement Analysis – Financial Results
- CP ALL Public Company Limited (CPALL.BK) Income Statement Analysis – Financial Results
- Eastern Resources Limited (EFE.AX) Income Statement Analysis – Financial Results
- Panram International Corp. (8088.TWO) Income Statement Analysis – Financial Results
- Comarch S.A. (CMR.WA) Income Statement Analysis – Financial Results
MicroTech Medical (Hangzhou) Co., Ltd. (2235.HK)
About MicroTech Medical (Hangzhou) Co., Ltd.
MicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables in the People's Republic of China and internationally. Its products include Equil Patch insulin pump systems, AiDEX continuous glucose monitoring systems, POCT analyzer systems, blood glucose monitoring systems, and closed-loop artificial pancreas. The company is also involved in engineering and technology research experimentation and development activities. MicroTech Medical (Hangzhou) Co., Ltd. was incorporated in 2011 and is headquartered in Hangzhou, the People's Republic of China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 248.35M | 173.54M | 151.40M | 75.28M | 51.86M |
| Cost of Revenue | 125.13M | 93.89M | 80.52M | 38.73M | 27.78M |
| Gross Profit | 123.22M | 79.66M | 70.88M | 36.54M | 24.08M |
| Gross Profit Ratio | 49.62% | 45.90% | 46.82% | 48.55% | 46.44% |
| Research & Development | 70.10M | 30.60M | 14.82M | 82.01M | 50.06M |
| General & Administrative | 15.90M | 42.29M | 42.02M | 5.97M | 1.87M |
| Selling & Marketing | 145.62M | 116.70M | 52.26M | 55.06M | 27.00M |
| SG&A | 161.52M | 158.99M | 94.27M | 61.02M | 28.88M |
| Other Expenses | 11.88M | 8.31M | 16.23M | 20.55M | 29.50M |
| Operating Expenses | 243.49M | 197.89M | 125.32M | 163.58M | 108.43M |
| Cost & Expenses | 368.62M | 291.78M | 205.84M | 202.32M | 136.21M |
| Interest Income | 68.24M | 55.72M | 23.32M | 2.38M | 848.00K |
| Interest Expense | 313.19K | 147.00K | 17.00K | 308.00K | 311.00K |
| Depreciation & Amortization | 11.17M | 10.48M | 8.33M | 5.48M | 3.43M |
| EBITDA | -114.60M | -21.71M | -39.80M | -121.27M | -79.89M |
| EBITDA Ratio | -46.15% | -12.51% | -26.28% | -161.09% | -154.03% |
| Operating Income | -120.27M | -32.19M | -48.12M | -126.75M | -83.32M |
| Operating Income Ratio | -48.43% | -18.55% | -31.79% | -168.38% | -160.65% |
| Total Other Income/Expenses | -4.58M | -2.85M | -29.00K | 5.79M | 5.74M |
| Income Before Tax | -124.85M | -35.04M | -48.15M | -121.25M | -78.61M |
| Income Before Tax Ratio | -50.27% | -20.19% | -31.80% | -161.07% | -151.58% |
| Income Tax Expense | 163.62K | 2.70M | 29.00K | -5.74M | -4.70M |
| Net Income | -125.02M | -37.75M | -48.18M | -115.51M | -73.91M |
| Net Income Ratio | -50.34% | -21.75% | -31.82% | -153.45% | -142.51% |
| EPS | -0.29 | -0.09 | -0.13 | -0.27 | -0.17 |
| EPS Diluted | -0.29 | -0.09 | -0.13 | -0.27 | -0.17 |
| Weighted Avg Shares Out | 425.68M | 425.74M | 373.16M | 423.53M | 423.53M |
| Weighted Avg Shares Out (Dil) | 425.68M | 425.74M | 373.16M | 423.53M | 423.53M |
Source: https://incomestatements.info
Category: Stock Reports